歌礼制药：地尼法司他治疗痤疮新药上市申请获受理

Core Viewpoint - The company, Gilead Sciences (1672.HK), has announced that its novel FASN inhibitor, ASC40, for the treatment of acne has received acceptance for a new drug application by the National Medical Products Administration of China [1] Group 1: Clinical Trial Results - ASC40 demonstrated significant improvement in moderate to severe acne compared to placebo in a randomized, double-blind, placebo-controlled, multi-center Phase III clinical trial, achieving all primary, key secondary, and secondary efficacy endpoints [1] - The drug exhibited good safety and tolerability profiles [1]